An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration

Molecular Biology of the Cell

Volumn 17, Issue 1, 2006, Pages 367-378

  Mazzieri, Roberta ^a   D'Alessio, Silvia ^a   Kenmoe, Richard Kamgang ^a   Ossowski, Liliana ^c   Blasi, Francesco ^a,b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR FPRL1; GLYCOSYLPHOSPHATIDYLINOSITOL; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEINASE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VERY LATE ACTIVATION ANTIGEN 3;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME BINDING; ENZYME STRUCTURE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELL MOVEMENT; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTEGRINS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE HYDROLASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

ANIMALIA;

EID: 30044445646     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E05-07-0635     Document Type: Article

References (51)

1. Aguirre-Ghiso, J. A., Kovalski, K., and Ossowski, L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104.
2. Aguirre-Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K., and Ossowski, L. (2001). Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38 (MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12, 863-879.
3. Andolfo, A., English, W., Resnati, M., Murphy, G., Blasi, F., and Sidenius, N. (2002). Metalloproteases cleave of the urokinase-type plasminogen activator receptor leads to exposure of epitopes not present in the intact soluble receptor. Thromb. Haemost. 88, 298-306.
4. Appella, E., Robinson, E. A., Ulrich, S. J., Stoppelli, M. P., Corti, A., Cassani, G., and Blasi, F. (1987). The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J. Biol. Chem. 262, 4437-4440.
5. Baggiolini, M., Dewald, B., and Moser, B. (1994). Interleukin 8 and related chemotactic cytokines-CXC and CC Chemokines. Adv. Immunol. 55, 97-179.
6. Beaufort, N., Leduc, D., Rousselle, J. C., Magdolen, V., Luther, T., Namane, A., Chignard, M., and Pidard, D. (2004). Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J. Immunol. 172, 540-549.
7. Blasi, F., and Carmeliet, P. (2002). uPAR: a versatile signaling orchestrator. Nat. Rev. Mol. Cell. Biol. 3, 932-943.
8. Blasi, F., Vassalli, J.-D., and Danø, K. (1987). Urokinase-type plasminogen activator: proenzyme, receptor and inhibitors. J. Cell Biol. 104, 801-804.
9. Chapman, H. A. (1997). Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9, 714-724.
10. Crowley, C. W., Cohen, R. L, Lucas, B. K., Liu, G., Shuman, M. A., and Levinson, A. D. (1993). Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA 90, 5021-5025.
11. Cunningham, O., Andolfo, A. P., Santovito, A. L., Iuzzolino, L., Blasi, F., and Sidenius, N. (2003). Differential lipid raft partitioning of the urokinase receptor regulates its biological functions and is controlled by receptor dimerization. EMBO J. 22, 5994-6003.
12. Danø, K., Romer, J., Nierlsen, B. S., Bjorn, S., Pyke, C., Rygaard, J., and Lund, L. R. (1999). Cancer Invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107, 120-127.
13. Degryse, B., Orlando, S., Resnati, M., Rabbani, S. A., and Blasi, F. (2001). Urokinase/urokinase receptor and vitronectin/αvβ3 integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 20, 2032-2043.
14. Degryse, B., Resnati, M., Czekay, R.-P., Loskutoff, D., and Blasi, F. (2005). Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J. Biol. Chem. 280, 24792-24803.
15. Degryse, B., Resnati, M., Rabbani, S. A., Villa, A., Fazioli, F., Blasi, F. (1999). Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis, and cytoskeleton reorganization in rat smooth muscle cells via the urokinase receptor. Blood 94, 649-662.
16. Estreicher, A., Wohlwend, A., Belin, D., Schleuning, W. D., and Vassalli, J.-D. (1989). Characterization of the cellular binding site for the urokinase-type plasminogen activator. J. Biol. Chem. 264, 1180-1189.
17. Fazioli, P., Resnati, M., Sidenius, N., Higashimoto, Y., Appella, E., and Blasi, F. (1997). The urokinase-sensitive region of the urokinase receptor is responsible for its potent chemotactic activity. EMBO J. 16, 7279-7286.
18. Furlan, F., Orlando, S., Laudanna, C., Resnati, M., Basso, V., Blasi, F., and Mondino, A. (2004). The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte migration and integrin-dependent cell adhesion. J. Cell Sci. 117, 2909-2916.
19. Gargiulo, L., Longanesi-Cattani, L, Bifulco, K., Franco, P., Raiola, R., Campiglia, P., Grieco, P., Peluso, G., Stoppelli, M. P., and Carriero, M. V. (2005). Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J. Biol. Chem. 280, 25225-25232.
20. Gyetko, M. R., Sud, S., Kendall, T., Fuller, J. A., Newstead, M. W., and Standiford, T. J. (2000). Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J. Immunol. 165, 1513-1519.
21. Høyer-Hansen, G., Ploug, M., Behrendt, N., Rønne, E., and Danø, K. (1997). Cell surface acceleration of urokinase-catalyzed receptor cleavage. Eur. J. Biochem. 243, 21-26.
22. Høyer-Hansen, G., Rønne, E., Solberg, H., Behrendt, N., Ploug, M., Lund, L. R., Ellis, V., and Danø, K. (1992). Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267, 18224-18229.
23. Jo, M., Thomas, K. S., O'Donnell, D. M., and Gonias, S. L. (2003). Epidermal growth factor receptor-dependent and -independent cell signaling pathways originating from the urokinase receptor. J. Biol. Chem. 278, 1642-1646.
24. Jo, M., Thomas, K. S., Marozkina, N., Amin, T. J., Silva, C. M., Parsons, S. J., and Gonias, S. L. (2005). Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J. Biol. Chem. 280, 17449-17457.
25. Kjøller, L. (2002). The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol. Chem. 383, 5-19.
26. Klein, C., Paul, J. I., Sauve, K., Schmidt, M. M., Arcangeli, L., Ransom, J., Truehart, J., Manfredi, J. P., Broach, J. R., and Murphy, A. J. (1998). Identification of surrogate agonists for the human FPRL1 receptor by autocrine selection in yeast. Nat. Biotechnol. 16, 1334-1337.
27. Koolwijk, P., Sidenius, N., Peters, E., Sier, C.F.M., Hanemaaijer, R., Blasi, F., and van Hinsbergh, V.W.M. (2001). Proteolysis of the urokinase-type plasminogen activator receptor by metalloprotease-12. Implication for angiogenesis in fibrin matrices. Blood 97, 3123-3131.
28. Liu, D., Aguirre-Ghiso, J. A., Estrada, Y., and Ossowski, L. (2002). EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457.
29. Llinas, P., Le Du, M. H., Gardsvoll, H., Danø, K., Ploug, M., Gilquin, B., Stura, E. A., and Menez, A. (2005). Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 24, 1655-1663.
30. May, A. E., Kanse, S. M., Lund, L. R., Gisler, R. H., Imhof, B. A., and Preissner, K. T. (1998). Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J. Exp. Med. 188, 1029-1037.
31. Min, H. Y., Doyle, L. V., Vitt, C. R., Zandonella, C. L., Stratton-Thomas, J. R., Shuman, M. A., and Rosenberg, A. (1996). Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 56, 2428-2433.
32. Neer, E. (1995). Heterotrimeric G proteins: organizers of transmembrane signals. Cell 80, 249-257.
33. Nguyen, D. H., Webb, D. J., Catling, A. D., Song, Q., Dhakephalkar, A., Weber, M. J., Ravichandran, K. S., and Gonias, S. L. (2000). Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway andMCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and She. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J. Biol. Chem. 275, 19382-19388.
34. Ossowski, L., and Aguirre Ghiso, J. A. (2000). Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12, 613-620.
35. Ploug, M., and Ellis, V. (1994). Structure-Function Relationship in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom a-neurotoxins. FEBS Lett. 349, 163-168.
36. Ploug, M., Rønne, E., Behrendt, N., Jensen, A. L., Blasi, F., and Danø, K. (1991). Cellular receptor for urokinase plasminogen activator: carboxyl terminal processing and membrane anchoring. J. Biol. Chem. 266, 1926-1933.
37. Preissner, K., Kanse, S. M., and May, A. E. (2000). Urokinase receptor: a molecular organizer in cellular communication. Curr. Opin. Cell Biol. 12, 621-628.
38. Ragno, P., Montuori, N., Covelli, B., Høyer-Hansen, G., and Rossi, G. (1998). Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells. Cancer Res. 58, 1315-1319.
39. Resnati, M., Guttinger, M., Valcamonica, S., Sidenius, N., Blasi, F., and Fazioli, F. (1996). Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15, 1572-1582.
40. Resnati, M., Pallavicini, I., Wang, Y. M., Oppenheim, J., Serhan, C. N., Romano, M., and Blasi, F. (2002). The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA 99, 1359-1364.
41. Riittinen, L., Limongi, P., Crippa, M. P., Conese, M., Hernandez-Marrero, L., Fazioli, F., and Blasi, F. (1996). Removal of domain D2 or D3 of the human urokinase receptor does not affect ligand affinity. FEBS Lett. 381, 1-6.
42. Roldan, A. L., Cubellis, M. V., Masucci, M. T., Behrendt, N., Lund, L. R., Danø, K., and Blasi, F. (1990). Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell-surface plasmin dependent proteolysis. EMBO J. 9, 467-474.
43. Rønne, E., Behrendt, N., Ellis, V., Ploug, M., Danø, K., and Høyer-Hansen, G. (1991). Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett. 288, 233-236.
44. Selleri, C., et al. (2005). Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 105, 2198-2206.
45. Sidenius, N., Sier, C.F.M., and Blasi, F. (2000). Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 475, 52-56.
46. Sidenius, N., and Blasi, F. (2003). The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 22, 205-222.
47. Trigwell, S., Wood, L., and Jones, P. (2000). Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck). Biochem. Biophys. Res. Commun. 278, 440-446.
48. Webb, D. J., Nguyen, D. H., and Gonias, S. L. (2000). Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and Matrigel invasion. J. Cell Sci. 113, 123-134.
49. Wei, Y., Czekay, R.-P., Robillard, L., Kugler, M. C., Zhang, F., Kim, K. K., Xiong, J.-P., Humphries, M. J., and Chapman, H. A. (2005). Regulation of α5β1 integrin conformation and function by urokinase receptor binding. J. Cell Biol. 168, 501-511.
50. Wei, Y., Eble, J. A., Wang, Z., Kreidberg, J. A., and Chapman, H. A. (2001). Urokinase receptor promotes β1 integrin function through interactions with integrin α5β1. Mol. Biol. Cell 12, 2975-2986.
51. Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V., and Chapman, H. A. (1996). Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555.